Tag: jurisdiction

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.

BEIJING, June 25, 2026 (GLOBE NEWSWIRE) -- DSC Holdings Ltd. (“DSC” or the “Company”) (NASDAQ: DSC), the AI application infrastructure for China’s used car industry, today announced that it has priced its initial public offering of 3,000,000 American depositary shares (“ADSs”) at US$17 per ADS, for a total offering size of approximately US$51 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents 20 Class A ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Global Market today under the ticker symbol “DSC.” The offering is expected to close on June 26, 2026, subject to customary closing conditions.

NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Prospect Floating Rate and Alternative Income Fund, Inc. (“Prospect Floating Rate and Alternative Income Fund” or the “Fund”), announced today that the Fund’s Board of Directors has declared the monthly “base” cash common shareholder distribution and its quarterly cash “bonus” common shareholder distribution for June 2026.

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).

CLAYMONT, Del., June 23, 2026 (GLOBE NEWSWIRE) -- Archimedes Tech SPAC Partners II Co. (Nasdaq: ATII), a publicly traded special purpose acquisition company (“ATII” or “Archimedes II”), today announced the filing with the U.S. Securities and Exchange Commission (the “SEC”), on June 22, 2026, of an amendment to the registration statement on Form S-4 (File No.: 333-295563) (as may be amended from time to time, the “Registration Statement”) previously filed in connection with the previously announced proposed business combination with Forge Nano, Inc. (“Forge Nano”). The Registration Statement includes a preliminary proxy statement/prospectus and has not yet been declared effective. The Registration Statement was filed by ATII Holdings Inc. (CIK 0002101833), ATII’s wholly-owned subsidiary (“Pubco”), and Forge Nano (CIK 0001719324) and is available free of charge at the SEC’s web site at www.sec.gov.